Picture of OliX Pharmaceuticals logo

226950 OliX Pharmaceuticals Share Price

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+3.59%
3m+71.63%
6m+1.49%
1yr-11.05%
Volume Change (%)
10d/3m+58.23%
Price vs... (%)
52w High-20.05%
50d MA+12.03%
200d MA+16.38%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value11.21
Price to Tang. Book12.05
Price to Free Cashflown/a
Price to Sales16.04
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-26.49%
Return on Equity-59.49%
Operating Margin-90.61%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueKR₩m1,130.332,474.273,674.369,320.3217,064.28n/an/a124.09%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/an/an/an/an/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of OliX Pharmaceuticals EPS forecast chart

Profile Summary

OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    June 30th, 2024
    Incorporated
    February 26th, 2010
    Public Since
    July 18th, 2018
    No. of Shareholders
    19,993
    No. of Employees
    72
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    kr flag iconKorea Exchange - KOSDAQ
    Shares in Issue
    16,973,797

    226950 Share Price Performance

    Upcoming Events for 226950

    Q3 2024 OliX Pharmaceuticals Inc Earnings Release

    Q4 2024 OliX Pharmaceuticals Inc Earnings Release

    Similar to 226950

    Picture of ABion logo

    ABion

    kr flag iconKorea Exchange - KOSDAQ

    Picture of ABL Bio logo

    ABL Bio

    kr flag iconKorea Exchange - KOSDAQ

    Picture of Amicogen logo

    Amicogen

    kr flag iconKorea Exchange - KOSDAQ

    Picture of AprilBio Co logo

    AprilBio Co

    kr flag iconKorea Exchange - KOSDAQ

    Picture of AptaBio Therapeutics logo

    AptaBio Therapeutics

    kr flag iconKorea Exchange - KOSDAQ

    FAQ